- Home
- PETS vs IVVD Comparison
PETS vs IVVD Comparison
Compare PETS & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | IVVD |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 692.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETS | IVVD |
|---|---|---|
| Price | $3.91 | $2.38 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.20 | ★ $8.33 |
| AVG Volume (30 Days) | 6.9M | ★ 12.4M |
| Earning Date | 02-02-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | $2.98 | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $1.57 | $0.35 |
| 52 Week High | $6.08 | $3.07 |
Technical Indicators
Market Signals| Indicator | PETS | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 55.26 |
| Support Level | $1.69 | $2.15 |
| Resistance Level | $4.05 | $2.59 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 92.49 | 60.40 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.